Articles tagged with Targeted Drug Delivery
University of Illinois researchers have developed a method to quantify drug delivery from nanoparticles inside a cell, providing new insights into the efficacy of therapy and mechanisms underlying cellular uptake. This breakthrough could lead to more effective treatments by controlling and manipulating drug release.
Scientists at the University of Texas Medical Branch have successfully treated rhesus macaques infected with Sudan ebolavirus using an RNA-based therapeutic called siRNA, administered via a lipid nanoparticle platform. The treatment was effective in preventing replication of the virus and improving survival rates.
A team of Russian physicists developed a method to use the magnetocaloric effect for targeted drug delivery to implants, avoiding rejection. The technique involves applying an external magnetic field to lower the temperature of a magnetic material, releasing a controlled dose of medication at the implant site.
Researchers at Texas A&M University have developed nanosystems that can cross the gastrointestinal tract and blood-brain barriers, enabling oral delivery of difficult-to-administer drugs. This approach uses non-competitive active transport to bind to cells, allowing the drug to be absorbed by the body.
Researchers found that pre-treatment with an Alk5 inhibitor enhances the delivery of ferumoxytol to tumors, allowing for improved imaging. The study demonstrates potential for Alk5 inhibitors to improve tumor imaging and diagnosis of solid tumors.
Researchers developed gel nano-capsules that can release medicine in response to temperature changes, improving the efficiency of targeted drug delivery. The innovation overcomes existing challenges, such as aggregation and electrostatic interactions.
Satish Nadig, a promising young researcher, has received the National Institutes of Health's Mentored Clinical Scientist Research Career Development Award. The $580,000 grant will support his three-year study on targeted drug delivery for organ transplantation, aiming to minimize harmful effects of immunosuppressant therapy.
Nanoparticulate drug carriers show promise in targeted cancer therapy, increasing therapeutic concentrations at tumor sites while minimizing harm to healthy tissues. This approach has the potential to improve treatment efficacy and reduce systemic toxicity.
Researchers at the Weizmann Institute of Science have created miniature 'flasks' that can accelerate chemical reactions by trapping molecules in a highly selective manner. The dynamic and reversible clusters can be reused multiple times, making them useful for applications such as drug delivery and industrial manufacturing.
Computational models suggest a new design for nanoparticles used in targeted drug delivery. The researchers proposed making more stable liposomes by incorporating a nanoparticle core and polymer tethers, which acts as a hub-and-spoke-like scaffold that helps the liposome to weather stresses and strains.
Nanoparticles wrapped in human platelet membranes deliver drugs to targeted sites, increasing therapeutic effects for diseased rats and mice. The platelet-membrane-coated nanoparticles selectively bind to damaged blood vessels and certain pathogens, minimizing the spread of bacteria and enhancing antibiotic efficacy.
Researchers at Columbia University developed a new method for targeted drug delivery to the lung, which may provide more effective treatments for many lung diseases. By delivering small volumes of drugs directly to the pathologic site, they aim to reduce adverse effects on other organs.
The University of Nottingham leads a £6.5m research project to create bespoke biomaterials for specific applications in regenerative medicine, drug delivery, and medical devices. The team aims to identify new materials that can control cell response and address unmet clinical needs.
Researchers at the University of Manchester developed heat-activated liposomes with antibody targeting capabilities, showing improved drug delivery to tumour tissue in mice. The combination approach resulted in a moderate improvement in animal survival, offering potential for novel targeted drug delivery strategies.
Researchers have developed nanoparticles that can efficiently transport charge-neutral oligonucleotide analogs into cells, enabling them to retain biological activity. This breakthrough delivery approach has the potential to treat various therapeutic targets.
Researchers have developed microneedles that can deliver drugs to specific areas within the eye, targeting two major diseases: glaucoma and corneal neovascularization. The treatment has shown promising results in reducing intraocular pressure and halting unwanted blood vessel growth.
University of Delaware researchers show that routine procedures in handling and processing nanocarrier solutions can alter their size and shape, affecting targeted drug delivery to cancer cells. The study's findings have significant implications for the production, storage, and use of nano-based drug delivery systems.
Researchers developed biodegradable nanomotors inspired by plant corkscrew structures for targeted drug delivery. The low-cost, plant-based microswimmers can efficiently navigate liquids with magnetic control.
Engineers have created a biological nanopore that acts as a selective door for DNA molecules to enter cells, potentially revolutionizing gene therapy and targeted drug delivery. The nanopore can be controlled to allow specific genetic information in specific cells, opening new possibilities for precision medicine.
A new process allows for the growth of highly customizable coatings of foam-like polymers from gases, enabling adjustable density and pore structure. This development has potential applications in medical, manufacturing, and high-tech research fields.
Researchers developed a nanogel-based delivery system targeting immunosuppressive drug mycophenolic acid at tissues associated with immune cells. The treatment showed improved survival rates and delayed kidney damage in mouse models of lupus.
A novel drug delivery strategy has been shown to neutralize mutant RNA toxicity and eliminate myotonia symptoms in mice with myotonic dystrophy. The approach uses antisense oligonucleotides and peptide-linked morpholino oligonucleotides to target the disease-causing mutation.
Researchers developed a novel approach to deliver cholesterol-conjugated small interfering RNAs (siRNAs) to liver cells using an endosomolytic polymer. The method significantly improves siRNA efficacy for targeted gene silencing, opening new possibilities for disease treatment.
Researchers at UGA have developed a new method for delivering drugs to mitochondria, increasing the effectiveness of cancer, Alzheimer's, and obesity treatments. The approach uses biodegradable nanoparticles to target the 'powerhouse of cells', resulting in improved survival rates for brain cells and reduced fat production.
Researchers engineered bacteria to provide accurate 3D images of tumors in mice, revealing bacterial location within the tumor. This breakthrough enables targeted cancer treatment and diagnosis.
A new class of nanoparticles has been developed to prevent premature drug release and ensure targeted delivery to tumors. The dual-responsive boronate cross-linked micelles (BCMs) can release drugs in response to acidic environments or mannitol, minimizing premature release and maximizing tumor targeting.
Clearside Biomedical aims to treat age-related macular degeneration and glaucoma with a new microinjection technology that targets the back of the eye. The technology developed by Georgia Tech and Emory University uses hollow microneedles to deliver therapeutics precisely to specific locations in the eye.
Phthalates, including dibutyl phthalate (DBP) and diethyl phthalate (DEP), are used in FDA-approved medications to target delivery of active ingredients. The study found over 100 products containing phthalates, with potential health effects of human exposure unknown.
Researchers have developed super-mini vehicles that can carry drugs and imaging agents into the body, revolutionizing medicine by improving drug solubility and bio-distribution. The devices use self-assembling nano-sized structures to cross membrane barriers and enable combination therapies.
Researchers at UCLA develop a new method for targeted drug delivery using nanotechnology. They demonstrate the ability to package drug-loaded 'nanodisks' into vault nanoparticles, which can hold hundreds of drugs and target specific cells in the body.
Tiny LNA-based compounds developed by Santaris Pharma A/S successfully inhibit entire microRNA families, targeting cancer, viral infections, and cardiovascular diseases. The high affinity and target specificity of these compounds enable functional inhibition without off-target effects.
Researchers used laser light to force cancer cells to take in chemotherapy drugs and fluorescent dyes, creating a potential delivery system. The technique also allowed them to target anti-Alzheimer's medicines to the brain non-invasively.
A new technique aims to open the blood-brain barrier, allowing targeted delivery of drugs to the brain. The goal is to reduce side effects and increase effectiveness of current treatments for Alzheimer's disease and other brain illnesses.
Researchers have developed a method to control drug delivery using nanoparticles, which can improve the therapeutic effects of colon cancer treatments. The new approach targets the lower intestine, overcoming existing barriers such as stomach acidity and rapid clearance.
Researchers developed a nanosponge-based delivery system that is three to five times more effective than direct injection in reducing tumor growth. The system uses biodegradable particles with predictable release characteristics, making it an attractive alternative for targeted cancer therapy.
Researchers have developed synthetic biomaterials that mimic cellular membranes, showing promise in targeted delivery of cancer drugs and gene therapy. The new materials, called dendrimersomes, offer stability, mechanical strength, and tunable properties.
The Phase II clinical study investigated the efficacy and tolerability of OptiNose's novel, intranasal sumatriptan product for treating migraine. The results showed high efficacy, with pain-free rates at two hours being 54% for the 10mg dose and 57% for the 20mg dose.
Researchers have developed PEGylated Polylysine dendrimers as a novel mechanism of drug delivery, targeting either the lymphatic system or bloodstream. The technology offers improved treatment options for diseases such as cancer, HIV, and lymphatic conditions worldwide.
Scientists have successfully grown and loaded empty nano containers with useful chemicals from a plant virus, opening up new areas of research in targeted drug delivery. The technology has potential applications in cancer treatment, delivering drugs directly to diseased cells while sparing healthy ones.
Five early stage companies at NJIT's Enterprise Development Center received significant funding to advance their technologies, including a drug to stop bleeding during brain injuries and a mattress to prevent bedsores. The grants will support training initiatives and strengthen the companies' paths to success.
A new study from Cornell University engineers tiny containers that deliver drugs with almost 100% efficiency to targeted cells. The technique mimics a natural immune response and could be used to treat cancer, blood disorders, and autoimmune diseases.
Researchers at Penn State have developed tiny particle syringes that can deliver specific drugs to diseased cells, reducing toxins in the body. The microcapsules are flexible and can be filled with a variety of substances, making them a potential solution for targeted treatment.
Researchers at Carnegie Mellon University have developed nanogels that can uniformly release encapsulated carbohydrate-based drugs, enabling targeted delivery to specific tissues like cancer cells. The nanogels are biodegradable and non-toxic, allowing for prolonged circulation time within the bloodstream.
Researchers have developed a new drug delivery method using nanoparticles that carries the chemotherapy drug doxorubicin deeper into solid tumors, improving its effectiveness. This treatment approach resulted in increased tumor growth prevention and longer survival times for mice compared to traditional methods.
Researchers at the University at Buffalo have developed a novel drug delivery system using nanocrystals of hydrophobic drugs, which can target tumors with comparable efficacy to conventional surfactant-based systems. The system eliminates the need for separate carriers, reducing toxicity and improving drug penetration.
A Purdue University researcher has shed light on the details of one mechanism by which targeted drug therapy is achieved. The understanding of how to deliver and unload a cancer drug can be extrapolated to other diseased cells, including those involved in arthritis, multiple sclerosis, and Crohn's disease.
Two Yale Biomedical Engineers, Erin Lavik and Tarek Fahmy, have received Early Career Translational Research Awards for their innovative projects on glaucoma treatment and autoimmune disease diagnosis. The awards support their research collaborations with clinical investigators and provide two years of funding.
Rutgers University researcher John Sinko has received a $1.7 million NIH MERIT award to continue his research on nanotechnology-based, targeted drug delivery systems for treating HIV-infected cells. The funding will support the design, development, and testing of novel anti-HIV drug delivery systems.
A cancer researcher is working on a targeted way to deliver drugs to specific cells, making treatment more precise and effective. The approach uses natural biomolecules to target diseased cells while leaving healthy ones alone.
Researchers have unveiled a new technique to characterize binding interactions of multivalent molecules designed for targeted drug delivery in cancer treatment. This method, using atomic force microscopy, shows promise for optimizing binding affinity and designing better antibodies.
Researchers developed nanoparticles that can target and deliver drugs to prostate cancer cells using aptamers, achieving highly specific and efficient tumour targeting. The bioconjugates successfully adhered to PSMA-positive prostate cancer cells and were rapidly internalised into the targeted cells.
A team at Georgia Institute of Technology has developed heat-controlled drug implants that can release medication over an extended period, targeting conditions like diabetes. The films, made from microparticles, could be triggered by blood glucose monitors to administer insulin or other medications.
A phase III study uses IL13-PE38QQR, a hybrid protein that attaches to specific receptors on tumor cells, to target residual GBM brain tumors. The treatment, convection-enhanced delivery, facilitates infusion of the drug into the brain, bypassing the blood-brain barrier.
Researchers have developed a three-way drug delivery system using vesicles, allowing for the simultaneous release of different materials in a single vehicle. This innovation could minimize toxic side effects and enhance the effectiveness of medications.
Researchers are exploring alternative methods for delivering drugs, including handheld electronic inhalers, dry powder injection and implantable microchips. These innovative systems have the potential to deliver precise doses of medication in a faster and more efficient manner than traditional hypodermic needles.